Point #7 - CRY & Medafor are not a good fit generally
I'm guessing that 80% of the MPH market is in non-cardiac markets, places where CRY has no presence or knowledge. For example, China, Japan, OB-GYN, ENT, neuro, ortho, trama, general surgery, etc. Then remember CRY covers perhpas 50% of the cardiac market. The result is that maybe CRY is a 10% fit, but the obvious implication is that CRY is a 90% non-fit.